{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:51:36Z","timestamp":1787997096056,"version":"build-2784847793"},"reference-count":84,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Vasoactive peptides constitute a heterogenous family of mediators exerting various physiological functions, mostly studied for their vasotropic effects and role as peripheral neurotransmitters\/neuromodulators, mainly involved in nociceptive transmission modulation. They have been divided into vasodilatory or vasoconstrictive peptides, according to their predominant effects on vascular tone. Recent research has shown in the Central Nervous System effects as transmitters and \u201cgrowth factor-like\u201d signals. Therefore, deregulation of their signaling systems has been thought to play a role in neural cell death and in the pathogenesis of neurodegenerative disorders, including Alzheimer\u2019s disease, since these peptides can regulate neuronal stress signaling, survival cascades, synaptic plasticity. This review considers evidence about the implication of neuropeptide systems in Alzheimer\u2019s disease while focusing mainly on calcitonin gene-related peptide-alpha. In vitro and in vivo studies have shown potential implications in its pathogenesis. It has been possibly proposed as a neuroprotective agent, considering not only its pleiotropic actions on blood vessels, neurovascular coupling, energy metabolism, but also its potential actions on neuronal, glial, and immune system stress signaling, which might also derive from its structural homology to amylin. Amylin signaling is thought to be disrupted in Alzheimer\u2019s disease, and amylin itself takes part in the composition of senile plaques. Calcitonin gene-related peptide-containing systems seem more closely related to Alzheimer\u2019s disease pathogenesis than other neuropeptidergic systems, and their regulation might represent an interesting mechanism in developing novel therapeutic approaches.<\/jats:p>","DOI":"10.31083\/j.jin2004107","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T02:14:27Z","timestamp":1641262467000},"source":"Crossref","is-referenced-by-count":9,"title":["Vasoactive neuropeptides and Alzheimer\u2019s disease: a systematic review focusing on calcitonin gene-related peptide"],"prefix":"10.31083","volume":"20","author":[{"given":"Giulio","family":"Papiri","sequence":"first","affiliation":[{"name":"Neurology Clinic, Azienda Ospedaliero Universitaria, Ospedali Riuniti di Ancona, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Luzzi","sequence":"first","affiliation":[{"name":"Neurology Clinic, Azienda Ospedaliero Universitaria, Ospedali Riuniti di Ancona, 60126 Ancona, Italy"},{"name":"Department of Experimental and Clinical Medicine, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Marcucci","sequence":"first","affiliation":[{"name":"Radiology Department, Azienda Ospedaliero Universitaria, Ospedali Riuniti di Ancona, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Vignini","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Section of Biochemistry, Biology and Physics, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Braak H, de Vos RA, Jansen EN, Bratzke H, Braak E. Neuropathological hallmarks of Alzheimer\u2019s and Parkinson\u2019s diseases. Progress in Brain Research. 1998; 117: 267\u2013285.","DOI":"10.1016\/S0079-6123(08)64021-2"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Braak H, Braak E. Staging of Alzheimer\u2019s disease-related neurofibrillary changes. Neurobiology of Aging. 1995; 16: 271\u2013284.","DOI":"10.1016\/0197-4580(95)00030-I"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"De Strooper B, Karran E. The Cellular Phase of Alzheimer\u2019s Disease. Cell. 2016; 164: 603\u2013615.","DOI":"10.1016\/j.cell.2015.12.056"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Nazem A, Sankowski R, Bacher M, Al-Abed Y. Rodent models of neuroinflammation for Alzheimer\u2019s disease. Journal of Neuroinflammation. 2015; 12: 74.","DOI":"10.1186\/s12974-015-0291-y"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ding Y, Ren J, Yu H, Yu W, Zhou Y. Porphyromonas gingivalis, a periodontitis causing bacterium, induces memory impairment and age-dependent neuroinflammation in mice. Immunity & Ageing. 2018; 15: 6.","DOI":"10.1186\/s12979-017-0110-7"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Mielke MM, Haughey NJ, Han D, An Y, Bandaru VVR, Lyketsos CG, et al. The Association between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer\u2019s Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. Journal of Alzheimer\u2019s Disease. 2017; 60: 819\u2013828.","DOI":"10.3233\/JAD-160925"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Zhuo J, Wang H, Pratic\u00f2 D. Is hyperhomocysteinemia an Alzheimer\u2019s disease (AD) risk factor, an AD marker, or neither? Trends in Pharmacological Sciences. 2011; 32: 562\u2013571.","DOI":"10.1016\/j.tips.2011.05.003"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Li JG, Chu J, Barrero C, Merali S, Pratic\u00f2 D. Homocysteine exacerbates \u03b2-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Annals of Neurology. 2014; 75: 851\u2013863.","DOI":"10.1002\/ana.24145"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Di Meco A, Li J, Barrero C, Merali S, Pratic\u00f2 D. Elevated levels of brain homocysteine directly modulate the pathological phenotype of a mouse model of tauopathy. Molecular Psychiatry. 2019; 24: 1696\u20131706.","DOI":"10.1038\/s41380-018-0062-0"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Blass JP. Brain metabolism and brain disease: Is metabolic deficiency the proximate cause of Alzheimer\u2019s dementia? Journal of Neuroscience Research. 2001; 66: 851\u2013856.","DOI":"10.1002\/jnr.10087"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Marambaud P, Dreses-Werringloer U, Vingtdeux V. Calcium signaling in neurodegeneration. Molecular Neurodegeneration. 2009; 4: 20.","DOI":"10.1186\/1750-1326-4-20"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Selkoe DJ. Alzheimer\u2019s disease is a synaptic failure. Science. 2002; 298: 789\u2013791.","DOI":"10.1126\/science.1074069"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bell KFS, Hardingham GE. The influence of synaptic activity on neuronal health. Current Opinion in Neurobiology. 2011; 21: 299\u2013305.","DOI":"10.1016\/j.conb.2011.01.002"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kashyap G, Bapat D, Das D, Gowaikar R, Amritkar RE, Rangarajan G, et al. Synapse loss and progress of Alzheimer\u2019s disease -a network model. Scientific Reports. 2019; 9: 6555.","DOI":"10.1038\/s41598-019-43076-y"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Tansey KE, Cameron D, Hill MJ. Genetic risk for Alzheimer\u2019s disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Medicine. 2018; 10: 14.","DOI":"10.1186\/s13073-018-0523-8"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"De Luca C, Colangelo AM, Alberghina L, Papa M. Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Frontiers in Cellular Neuroscience. 2018; 12: 459.","DOI":"10.3389\/fncel.2018.00459"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Li J, Pratic\u00f2 D. High levels of homocysteine results in cerebral amyloid angiopathy in mice. Journal of Alzheimer\u2019s Disease. 2015; 43: 29\u201335.","DOI":"10.3233\/JAD-141101"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genetics in Medicine. 2016; 18: 421\u2013430.","DOI":"10.1038\/gim.2015.117"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Molecular Medicine. 2016; 8: 595\u2013608.","DOI":"10.15252\/emmm.201606210"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Mufson EJ, Counts SE, Ginsberg SD, Mahady L, Perez SE, Massa SM, et al. Nerve Growth Factor Pathobiology During the Progression of Alzheimer\u2019s Disease. Frontiers in Neuroscience. 2019; 13: 533.","DOI":"10.3389\/fnins.2019.00533"},{"key":"ref21","unstructured":"Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ. Pathogenic microbes, the microbiome, and Alzheimer\u2019s disease (AD). Frontiers in Aging Neuroscience. 2014; 6: 127."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Montagne A, Nation DA, Pa J, Sweeney MD, Toga AW, Zlokovic BV. Brain imaging of neurovascular dysfunction in Alzheimer\u2019s disease. Acta Neuropathologica. 2016; 131: 687\u2013707.","DOI":"10.1007\/s00401-016-1570-0"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression. Cell Research. 2019; 29: 787\u2013803.","DOI":"10.1038\/s41422-019-0216-x"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Xiao S, Chan P, Wang T, Hong Z, Wang S, Kuang W, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer\u2019s dementia. Alzheimer\u2019s Research & Therapy. 2021; 13: 62.","DOI":"10.1186\/s13195-021-00795-7"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Poon CH, Wang Y, Fung M, Zhang C, Lim LW. Rodent Models of Amyloid-Beta Feature of Alzheimer\u2019s Disease: Development and Potential Treatment Implications. Aging and Disease. 2020; 11: 1235.","DOI":"10.14336\/AD.2019.1026"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer\u2019s Disease. The New England Journal of Medicine. 2018; 378: 321\u2013330.","DOI":"10.1056\/NEJMoa1705971"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer\u2019s disease. Nature Reviews Neurology. 2019; 15: 73\u201388.","DOI":"10.1038\/s41582-018-0116-6"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Plotkin SS, Cashman NR. Passive immunotherapies targeting a\u03b2 and tau in Alzheimer\u2019s disease. Neurobiology of Disease. 2020; 144: 105010.","DOI":"10.1016\/j.nbd.2020.105010"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Forloni G, Balducci C. Alzheimer\u2019s Disease, Oligomers, and Inflammation. Journal of Alzheimer\u2019s Disease. 2018; 62: 1261\u20131276.","DOI":"10.3233\/JAD-170819"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RD. Shift in brain metabolism in late onset Alzheimer\u2019s disease: implications for biomarkers and therapeutic interventions. Molecular Aspects of Medicine. 2011; 32: 247\u2013257.","DOI":"10.1016\/j.mam.2011.10.005"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Wang R, Reddy PH. Role of Glutamate and NMDA Receptors in Alzheimer\u2019s Disease. Journal of Alzheimer\u2019s Disease. 2017; 57: 1041\u20131048.","DOI":"10.3233\/JAD-160763"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"van Marum RJ. Update on the use of memantine in Alzheimer\u2019s disease. Neuropsychiatric Disease and Treatment. 2009; 5: 237\u2013247.","DOI":"10.2147\/NDT.S4048"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ. Memantine in moderate-to-severe Alzheimer\u2019s disease. The New England Journal of Medicine. 2003; 348: 1333\u20131341.","DOI":"10.1056\/NEJMoa013128"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Autio J, Stenb\u00e4ck V, Gagnon DD, Lepp\u00e4luoto J, Herzig KH. (Neuro) Peptides, Physical Activity, and Cognition. Journal of Clinical Medicine. 2020; 9: 2592.","DOI":"10.3390\/jcm9082592"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"van den Pol AN. Neuropeptide transmission in brain circuits. Neuron. 2012; 76: 98\u2013115.","DOI":"10.1016\/j.neuron.2012.09.014"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Sams-Nielsen A, Orskov C, Jansen-Olesen I. Pharmacological evidence for CGRP uptake into perivascular capsaicin sensitive nerve terminals. British Journal of Pharmacology. 2001; 132: 1145\u20131153.","DOI":"10.1038\/sj.bjp.0703910"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Pinhasov A, Nesher E, Gross M, Turgeman G, Kreinin A, Yadid G. The Role of the PACAP Signaling System in Depression. Current Pharmaceutical Design. 2011; 17: 990\u20131001.","DOI":"10.2174\/138161211795589328"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Singh Y, Gupta G, Shrivastava B, Dahiya R, Tiwari J, Ashwathanarayana M, et al. Calcitonin gene-related peptide (CGRP): a novel target for Alzheimer\u2019s disease. CNS Neuroscience & Therapeutics. 2017; 23: 457\u2013461.","DOI":"10.1111\/cns.12696"},{"key":"ref39","unstructured":"St-Gelais F, Jomphe C, Trudeau L. The role of neurotensin in central nervous system pathophysiology: what is the evidence? Journal of Psychiatry & Neuroscience. 2006; 31: 229\u2013245."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Haase N, Herse F, Spallek B, Haase H, Morano I, Qadri F, et al. Amyloid-\u03b2 peptides activate \u03b11-adrenergic cardiovascular receptors. Hypertension. 2013; 62: 966\u2013972.","DOI":"10.1161\/HYPERTENSIONAHA.113.01348"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Niwa K, Porter VA, Kazama K, Cornfield D, Carlson GA, Iadecola C. A\u03b2-peptides enhance vasoconstriction in cerebral circulation. American Journal of Physiology-Heart and Circulatory Physiology. 2001; 281: H2417\u2013H2424.","DOI":"10.1152\/ajpheart.2001.281.6.H2417"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Diwakar L, Gowaikar R, Chithanathan K, Gnanabharathi B, Tomar DS, Ravindranath V. Endothelin-1 mediated vasoconstriction leads to memory impairment and synaptic dysfunction. Scientific Reports. 2021; 11: 4868.","DOI":"10.1038\/s41598-021-84258-x"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Chen X, Du Y, Chen L. Neuropeptides Exert Neuroprotective Effects in Alzheimer\u2019s Disease. Frontiers in Molecular Neuroscience. 2019; 11: 493.","DOI":"10.3389\/fnmol.2018.00493"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Sol\u00e9s-Tarr\u00e9s I, Cabezas-Llobet N, Vaudry D, Xifr\u00f3 X. Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide Against Cognitive Decline in Neurodegenerative Diseases. Frontiers in Cellular Neuroscience. 2020; 14: 221.","DOI":"10.3389\/fncel.2020.00221"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Rat D, Schmitt U, Tippmann F, Dewachter I, Theunis C, Wieczerzak E, et al. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer\u2019s disease-like pathology in amyloid precursor protein-transgenic mice. FASEB Journal. 2011; 25: 3208\u20133218.","DOI":"10.1096\/fj.10-180133"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"de Souza FRO, Ribeiro FM, Lima PMD. Implications of VIP and PACAP in Parkinson\u2019s Disease: what do we Know so Far? Current Medicinal Chemistry. 2021; 28: 1703\u20131715.","DOI":"10.2174\/0929867327666200320162436"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Van C, Condro MC, Lov K, Zhu R, Ricaflanca PT, Ko HH, et al. PACAP\/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. Journal of Molecular Neuroscience. 2019; 68: 439\u2013451.","DOI":"10.1007\/s12031-018-1137-8"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Schou WS, Ashina S, Amin FM, Goadsby PJ, Ashina M. Calcitonin gene-related peptide and pain: a systematic review. The Journal of Headache and Pain. 2017; 18: 34.","DOI":"10.1186\/s10194-017-0741-2"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Charles A. The pathophysiology of migraine: implications for clinical management. The Lancet. Neurology. 2018; 17: 174\u2013182.","DOI":"10.1016\/S1474-4422(17)30435-0"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Warfvinge K, Edvinsson L, Pickering D, Sheykhzade M. The Presence of Calcitonin Gene-Related Peptide and its Receptors in Rat, Pig and Human Brain: Species Differences in Calcitonin Gene-Related Peptide Pharmacology. Pharmacology. 2019; 104: 332\u2013341.","DOI":"10.1159\/000502471"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Hay DL, Garelja ML, Poyner DR, Walker CS. Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25. British Journal of Pharmacology. 2018; 175: 3\u201317.","DOI":"10.1111\/bph.14075"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Walker CS, Conner AC, Poyner DR, Hay DL. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends in Pharmacological Sciences. 2010; 31: 476\u2013483.","DOI":"10.1016\/j.tips.2010.06.006"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Russell FA, King R, Smillie S, Kodji X, Brain SD. Calcitonin gene-related peptide: physiology and pathophysiology. Physiological Reviews. 2014; 94: 1099\u20131142.","DOI":"10.1152\/physrev.00034.2013"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Rees TA, Gingell J, Siow A, Harris P, Brimble M, Hay D, et al. Differential internalisation of the CGRP and AMY 1 receptor. The FASEB Journal. 2020; 34: 1\u20131.","DOI":"10.1096\/fasebj.2020.34.s1.02530"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Gingell JJ, Hendrikse ER, Hay DL. New Insights into the Regulation of CGRP-Family Receptors. Trends in Pharmacological Sciences. 2019; 40: 71\u201383.","DOI":"10.1016\/j.tips.2018.11.005"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Routledge SJ, Simms J, Clark A, Yeung HY, Wigglesworth MJ, Dickerson IM, et al. Receptor component protein, an endogenous allosteric modulator of family B G protein coupled receptors. Biochimica Et Biophysica Acta (BBA) - Biomembranes. 2020; 1862: 183174.","DOI":"10.1016\/j.bbamem.2019.183174"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Ferrero H, Larrayoz IM, Gil-Bea FJ, Mart\u00ednez A, Ram\u00edrez MJ. Adrenomedullin, a Novel Target for Neurodegenerative Diseases. Molecular Neurobiology. 2018; 55: 8799\u20138814.","DOI":"10.1007\/s12035-018-1031-y"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Zhai L, Sakurai T, Kamiyoshi A, Ichikawa-Shindo Y, Kawate H, Tanaka M, et al. Endogenous calcitonin gene-related peptide suppresses ischemic brain injuries and progression of cognitive decline. Journal of Hypertension. 2018; 36: 876\u2013891.","DOI":"10.1097\/HJH.0000000000001649"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Schebesch K, Herbst A, Bele S, Sch\u00f6del P, Brawanski A, Stoerr E, et al. Calcitonin-gene related peptide and cerebral vasospasm. Journal of Clinical Neuroscience. 2013; 20: 584\u2013586.","DOI":"10.1016\/j.jocn.2012.07.006"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Morton RE, St. John PD, Tyas SL. Migraine and the risk of all\u2010cause dementia, Alzheimer\u2019s disease, and vascular dementia: a prospective cohort study in community\u2010dwelling older adults. International Journal of Geriatric Psychiatry. 2019; 34: 1667\u20131676.","DOI":"10.1002\/gps.5180"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Ringman JM, Romano JD, Medina LD, Rodriguez-Agudelo Y, Schaffer B, Varpetian A, et al. Increased prevalence of significant recurrent headache in preclinical familial Alzheimer\u2019s disease mutation carriers. Dementia and Geriatric Cognitive Disorders. 2008; 25: 380\u2013384.","DOI":"10.1159\/000121986"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Borkum JM. CGRP and Brain Functioning: Cautions for Migraine Treatment. Headache. 2019; 59: 1339\u20131357.","DOI":"10.1111\/head.13591"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Vause CV, Durham PL. Calcitonin gene-related peptide differentially regulates gene and protein expression in trigeminal glia cells: findings from array analysis. Neuroscience Letters. 2010; 473: 163\u2013167.","DOI":"10.1016\/j.neulet.2010.01.074"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Harzenetter MD, Novotny AR, Gais P, Molina CA, Altmayr F, Holzmann B. Negative regulation of TLR responses by the neuropeptide CGRP is mediated by the transcriptional repressor ICER. Journal of Immunology. 2007; 179: 607\u2013615.","DOI":"10.4049\/jimmunol.179.1.607"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Rossetti I, Zambusi L, Finardi A, Bodini A, Provini L, Furlan R, et al. Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 2018; 323: 94\u2013104.","DOI":"10.1016\/j.jneuroim.2018.07.005"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"N\u2019Diaye A, Gannesen A, Borrel V, Maillot O, Enault J, Racine P, et al. Substance P and Calcitonin Gene-Related Peptide: Key Regulators of Cutaneous Microbiota Homeostasis. Frontiers in Endocrinology. 2017; 8: 15.","DOI":"10.3389\/fendo.2017.00015"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Aresti Sanz J, El Aidy S. Microbiota and gut neuropeptides: a dual action of antimicrobial activity and neuroimmune response. Psychopharmacology. 2019; 236: 1597\u20131609.","DOI":"10.1007\/s00213-019-05224-0"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs A, Telegdy G. Effects of CGRP on active avoidance behavior in rats. Physiology & Behavior. 1995; 58: 429\u2013435.","DOI":"10.1016\/0031-9384(95)00066-R"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Angelucci F, Ellenbroek BA, El Khoury A, Math\u00e9 AA. CGRP in a gene-environment interaction model for depression: effects of antidepressant treatment. Acta Neuropsychiatrica. 2019; 31: 93\u201399.","DOI":"10.1017\/neu.2018.31"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Math\u00e9 AA, Hertel P, Nomikos GG, Gruber S, Math\u00e9 JM, Svensson TH. The psychotomimetic drugs D-amphetamine and phencyclidine release calcitonin gene-related peptide in the limbic forebrain of the rat. Journal of Neuroscience Research. 1996; 46: 316\u2013323.","DOI":"10.1002\/(SICI)1097-4547(19961101)46:3<316::AID-JNR4>3.3.CO;2-W"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Wimalawansa SJ, MacIntyre I. The presence of calcitonin gene-related peptide in human cerebrospinal fluid. Brain. 1987; 110: 1647\u20131655.","DOI":"10.1093\/brain\/110.6.1647"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Math\u00e9 AA, Agren H, Lindstr\u00f6m L, Theodorsson E. Increased concentration of calcitonin gene-related peptide in cerebrospinal fluid of depressed patients. a possible trait marker of major depressive disorder. Neuroscience Letters. 1994; 182: 138\u2013142.","DOI":"10.1016\/0304-3940(94)90782-X"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Math\u00e9 AA, Agren H, Wallin A, Blennow K. Calcitonin gene-related peptide and calcitonin in the CSF of patients with dementia and depression: possible disease markers. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2002; 26: 41\u201348.","DOI":"10.1016\/S0278-5846(01)00219-6"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Narimatsu N, Harada N, Kurihara H, Nakagata N, Sobue K, Okajima K. Donepezil improves cognitive function in mice by increasing the production of insulin-like growth factor-i in the hippocampus. The Journal of Pharmacology and Experimental Therapeutics. 2009; 330: 2\u201312.","DOI":"10.1124\/jpet.108.147280"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Knyih\u00e1r-Csillik E, Boncz I, S\u00e1ry G, Nemcs\u00f3k J, Csillik B. Parabrachial origin of calcitonin gene-related peptide-immunoreactive axons innervating Meynert\u2019s basal nucleus. Experimental Neurology. 1999; 157: 268\u2013276.","DOI":"10.1006\/exnr.1999.7050"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Csillik B, Rakic P, Knyih\u00e1r-Csillik E. Peptidergic innervation and the nicotinic acetylcholine receptor in the primate basal nucleus. The European Journal of Neuroscience. 1998; 10: 573\u2013585.","DOI":"10.1046\/j.1460-9568.1998.00066.x"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Na H, Gan Q, Mcparland L, Yang JB, Yao H, Tian H, et al. Characterization of the effects of calcitonin gene-related peptide receptor antagonist for Alzheimer\u2019s disease. Neuropharmacology. 2020; 168: 108017.","DOI":"10.1016\/j.neuropharm.2020.108017"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Bowman GL, Dayon L, Kirkland R, Wojcik J, Peyratout G, Severin IC, et al. Blood-brain barrier breakdown, neuroinflammation, and cognitive decline in older adults. Alzheimer\u2019s & Dementia. 2018; 14: 1640\u20131650.","DOI":"10.1016\/j.jalz.2018.06.2857"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Wang E, Zhu H, Wang X, Gower AC, Wallack M, Blusztajn JK, et al. Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer\u2019s Disease Mouse Model. Journal of Alzheimer\u2019s Disease. 2017; 56: 47\u201361.","DOI":"10.3233\/JAD-160677"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Mohamed LA, Zhu H, Mousa YM, Wang E, Qiu WQ, Kaddoumi A. Amylin Enhances Amyloid-\u03b2 Peptide Brain to Blood Efflux across the Blood-Brain Barrier. Journal of Alzheimer\u2019s Disease. 2017; 56: 1087\u20131099.","DOI":"10.3233\/JAD-160800"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacological Reviews. 2015; 67: 564\u2013600.","DOI":"10.1124\/pr.115.010629"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Palmiter RD. The Parabrachial Nucleus: CGRP Neurons Function as a General Alarm. Trends in Neurosciences. 2018; 41: 280\u2013293.","DOI":"10.1016\/j.tins.2018.03.007"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Saido T, Leissring MA. Proteolytic degradation of amyloid \u03b2-protein. Cold Spring Harbor Perspectives in Medicine. 2011; 2: a006379.","DOI":"10.1101\/cshperspect.a006379"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Bennett RG, Duckworth WC, Hamel FG. Degradation of Amylin by Insulin-degrading Enzyme. Journal of Biological Chemistry. 2000; 275: 36621\u201336625.","DOI":"10.1074\/jbc.M006170200"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/20\/4\/10.31083\/j.jin2004107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T15:34:34Z","timestamp":1732721674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/20\/4\/10.31083\/j.jin2004107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["S0219-6352(21)00254-0"],"URL":"https:\/\/doi.org\/10.31083\/j.jin2004107","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,30]]},"article-number":"1059"}}